Prometrium and Acetaminophen Interaction: What You Need to Know

Does Prometrium Interact With Acetaminophen?

The short answer is no clinically significant pharmacokinetic interaction has been documented between Prometrium and acetaminophen at standard doses. Both compounds undergo hepatic biotransformation, which creates a theoretical area of concern, but their primary metabolic pathways are distinct enough that one does not meaningfully inhibit or induce the other under normal therapeutic conditions.

The Prometrium FDA prescribing information lists no direct contraindication with acetaminophen, and the acetaminophen monograph does not flag progestogens as a drug class to avoid. A 2020 review of progesterone pharmacokinetics published in Steroids confirmed that micronized progesterone is processed predominantly through CYP3A4 with secondary involvement of CYP2C19 and that no competitive inhibition with analgesics of the para-aminophenol class has been reported.

The conversation does not end at "no interaction." Women on Prometrium are typically perimenopausal or postmenopausal, an age group that may also use acetaminophen regularly for musculoskeletal pain, headaches, or sleep-associated discomfort. Understanding the exact metabolic terrain of each drug gives prescribers and patients the context needed to use both safely.

Why Hepatic Overlap Matters Even Without a Direct Interaction

Prometrium is dissolved in peanut oil and formulated as a soft gelatin capsule specifically to improve oral bioavailability of micronized progesterone, which undergoes extensive first-pass hepatic metabolism. After absorption, the liver converts progesterone to 5-alpha-pregnanolone, 5-beta-pregnanolone, and related metabolites, primarily through CYP3A4 and partially through CYP2C19. The FDA label for Prometrium notes that oral bioavailability is around 10% relative to intramuscular administration, which illustrates just how aggressively the liver handles this molecule.

Acetaminophen takes a different set of routes. Approximately 90% is conjugated directly via UGT1A glucuronidation and sulfation, generating non-toxic products cleared by the kidneys. The remaining 5 to 10% is oxidized by CYP2E1 (and to a lesser degree CYP3A4 and CYP1A2) to produce N-acetyl-p-benzoquinone imine (NAPQI), the hepatotoxic intermediate that glutathione normally neutralizes. At therapeutic doses, glutathione supply is adequate. At doses above 4,000 mg/day, or lower in the presence of glutathione depletion (alcohol, fasting, liver disease), NAPQI accumulates and causes hepatocellular injury. The FDA's acetaminophen safety guidance recommends a maximum of 4,000 mg/day for healthy adults, with clinical practice guidelines commonly recommending 3,000 mg/day as a more conservative ceiling.

The shared reliance on liver tissue, not any single enzyme overlap, is where the concern sits. If baseline hepatic function is reduced, both drugs may clear more slowly and their respective metabolites may accumulate.

How Prometrium Is Metabolized: A Closer Look

Understanding why the Prometrium-acetaminophen pairing is generally low-risk requires a precise picture of progesterone metabolism.

CYP3A4 and CYP2C19 as Primary Enzymes

Micronized progesterone is an endogenous steroid, and the liver treats it accordingly. CYP3A4 handles the bulk of first-pass oxidative conversion. CYP2C19 contributes a secondary route that gains relative importance in individuals who are CYP3A4 poor metabolizers. A 2003 pharmacokinetic study published in Clinical Pharmacokinetics documented significant interindividual variability in progesterone AUC (area under the curve) values after oral dosing, consistent with the known polymorphic expression of CYP3A4 in the general population.

This variability matters clinically. A woman who is a CYP3A4 poor metabolizer may achieve progesterone blood levels up to three times higher than an extensive metabolizer at the same 200 mg dose. Adding a strong CYP3A4 inhibitor (like ketoconazole or ritonavir) would amplify this effect markedly. Acetaminophen is not a CYP3A4 inhibitor at any therapeutic dose, which is one reason the interaction risk is low.

Phase II Conjugation and Renal Clearance

After Phase I oxidation, progesterone metabolites undergo glucuronidation and sulfation before renal excretion. Interestingly, acetaminophen also relies heavily on UGT enzymes for Phase II conjugation. If both compounds were simultaneously saturating UGT capacity, competition for conjugation sites could theoretically slow clearance of one or both. At clinical doses of each drug taken together, that saturation threshold is not reached. The scenario becomes more plausible only if acetaminophen doses are at or near the daily maximum over extended periods in a woman who already has mildly impaired hepatic reserve.

Prometrium and Existing Liver Conditions

The Prometrium FDA label carries a warning that oral progesterone should be used with caution in individuals with a history of liver disease. Hepatic impairment is addressed in the label as a condition requiring individualized dosing. Women with known liver disease taking Prometrium face a meaningful restriction on how much hepatic metabolic capacity is available, which makes co-administered hepatically cleared drugs like acetaminophen more consequential.

How Acetaminophen Is Metabolized: The NAPQI Pathway

Acetaminophen's safety profile is among the most studied of any over-the-counter analgesic, yet it remains the leading cause of acute liver failure in the United States. The CDC reports that acetaminophen overdose accounts for roughly 50% of acute liver failure cases in the U.S. Annually.

The Three Metabolic Routes

1. Glucuronidation via UGT1A (approximately 55 to 60% of a therapeutic dose)
2. Sulfation via SULT1A1 (approximately 25 to 30% of a therapeutic dose)
3. CYP2E1/CYP3A4-mediated oxidation to NAPQI (approximately 5 to 10% of a therapeutic dose)

At doses up to 3,000 mg/day in a healthy adult, glutathione stores remain sufficient to quench NAPQI as fast as it is generated. A 2011 review in Hepatology calculated that glutathione depletion of greater than 70% is required before hepatocellular injury begins to occur, and that threshold is not met at therapeutic doses in individuals with healthy livers.

When the Risk Profile Changes

The NAPQI pathway becomes dangerous under three conditions: supratherapeutic dosing (above 4,000 mg/day), chronic alcohol use (which upregulates CYP2E1 while depleting glutathione), and pre-existing hepatic disease. Women taking Prometrium who also drink alcohol regularly, have non-alcoholic fatty liver disease, or have hepatitis should treat acetaminophen with the same caution they would apply to a scheduled medication, not a casual over-the-counter purchase.

Pharmacodynamic Considerations: Does Prometrium Affect Acetaminophen's Pain-Relieving Effect?

At the receptor level, progesterone and acetaminophen do not compete for the same targets. Acetaminophen's analgesic mechanism is still under investigation but appears to involve inhibition of cyclooxygenase enzymes in the central nervous system, activation of descending serotonergic pathways, and possible endocannabinoid modulation. Progesterone acts through nuclear progesterone receptors (PR-A and PR-B) and membrane-associated receptors with no direct overlap with these analgesic pathways.

One area where progesterone does have indirect relevance to pain is its neuroactive metabolite allopregnanolone. Allopregnanolone is a positive allosteric modulator of GABA-A receptors and may produce mild sedative and anxiolytic effects, particularly after oral Prometrium doses. A clinical pharmacology paper in the Journal of Clinical Endocrinology and Metabolism described the sedation observed in healthy women after 300 mg oral micronized progesterone as equivalent to a low benzodiazepine-like effect. If a woman takes Prometrium at bedtime (a common clinical strategy to capitalize on this sedation) and then takes a combination acetaminophen-diphenhydramine sleep product, the central nervous system depression could add. This is not a Prometrium-acetaminophen issue per se, but it illustrates why checking every ingredient in a combination OTC product matters.

Severity Classification: Where Does This Interaction Sit on the DDI Scale?

Drug interaction databases use tiered severity classifications. The most widely used systems include Lexicomp, Micromedex, and the FDA's drug interaction guidance categories. Across all three systems, Prometrium combined with plain acetaminophen at therapeutic doses falls into a "no known interaction" or "minor" category, meaning no dose adjustment is routinely required and no contraindication exists.

For context, the FDA interaction severity framework distinguishes:

• Contraindicated: The risks outweigh all benefits; do not combine.
• Serious: Use only if benefits justify risks; requires monitoring.
• Significant: Use with monitoring; consider alternatives.
• Minor: Clinically inconsequential under standard conditions.

The Prometrium-acetaminophen pairing sits at minor to no interaction for most patients. It moves toward significant only when acetaminophen is taken chronically above 2,000 to 3,000 mg/day in patients with pre-existing hepatic compromise or heavy alcohol use. A 2022 joint statement from the American Association for the Study of Liver Diseases (AASLD) reinforced that acetaminophen below 2,000 mg/day is acceptable even in patients with compensated cirrhosis, a position that frames the risk threshold precisely.

What the Prometrium Label Actually Says About Drug Interactions

The Prometrium prescribing information identifies CYP3A4 inhibitors and inducers as clinically relevant interactors. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) may increase progesterone exposure. Strong inducers (rifampin, carbamazepine, phenytoin) may reduce efficacy. The full Prometrium FDA label does not list acetaminophen in its drug interactions section, because acetaminophen does not meaningfully inhibit or induce CYP3A4 at clinical doses.

Monitoring Recommendations for Women Taking Both

Standard clinical practice does not require additional laboratory monitoring solely because a patient is combining Prometrium with occasional acetaminophen. The picture changes with chronicity and dose.

Baseline and Periodic Liver Function Testing

Women starting Prometrium as part of menopausal hormone therapy (MHT) should have baseline liver function tests (LFTs) documented before initiation, per general hormone therapy prescribing practice. The Endocrine Society's 2022 clinical practice guideline on menopause management recommends that hepatic status be assessed before initiating any oral progestogen-containing regimen. Endocrine Society guidelines are available here. If LFTs show elevations at baseline, periodic monitoring every three to six months is reasonable.

Adding chronic acetaminophen to this picture raises the monitoring priority. If a patient is taking 2,000 mg or more of acetaminophen daily for a chronic pain condition, an annual or semi-annual LFT panel is a defensible clinical decision even in the absence of any specific guideline mandate.

Red Flag Symptoms to Report

Patients should be counseled to report any of the following to their provider promptly:

• Jaundice or yellowing of the skin or eyes
• Dark urine (tea-colored)
• Right upper quadrant abdominal pain or tenderness
• Unexplained nausea or fatigue lasting more than a few days
• Significant pruritus (itching) without rash

These are the classic signs of hepatocellular stress that would indicate a need for immediate LFT measurement and consideration of dose reduction or drug discontinuation.

Patient Counseling: Practical Guidance for Everyday Use

Clinical guidelines and pharmacokinetic data translate into five practical points for patients.

Point 1: Occasional Use Is Not a Problem

A woman on Prometrium 200 mg for 12 days each cycle who takes 1,000 mg of acetaminophen for a headache or mild pain is not at meaningful risk. Standard short-course acetaminophen use at doses at or below 3,000 mg/day, in the absence of liver disease or heavy alcohol use, does not require any adjustment to the Prometrium regimen.

Point 2: Check Combination Products Carefully

Acetaminophen appears in more than 600 over-the-counter and prescription products. The FDA's guidance on combination acetaminophen products warns that inadvertent double-dosing from multiple OTC products is a leading cause of accidental acetaminophen overdose. Women on Prometrium who use sleep aids, cold medications, or prescription pain relievers should check every label for acetaminophen content before combining products.

Point 3: Time Prometrium at Bedtime

The Prometrium label explicitly recommends bedtime dosing to minimize the subjective sedation from allopregnanolone production. A woman who takes Prometrium at night and takes acetaminophen only during the day, as needed, separates any theoretical overlap in hepatic processing by several hours, a practical strategy that further reduces any residual concern.

Point 4: Alcohol Changes the Equation

Regular alcohol consumption upregulates CYP2E1, lowers glutathione reserves, and increases the fraction of acetaminophen converted to NAPQI. Women who drink more than one drink per day should follow the conservative 2,000 mg/day acetaminophen ceiling regardless of Prometrium status. Combining regular alcohol, daily acetaminophen at moderate-to-high doses, and oral progesterone in the context of pre-existing fatty liver represents the highest-risk scenario for hepatic stress in this patient population.

Point 5: NSAIDs Are Not Automatically Safer

Some women or clinicians may consider switching from acetaminophen to ibuprofen or naproxen to sidestep the hepatic concern entirely. That trade-off introduces different risks: non-steroidal anti-inflammatory drugs (NSAIDs) carry gastrointestinal, cardiovascular, and renal risks that may be more problematic in perimenopausal and postmenopausal women than the theoretical hepatic overlap with acetaminophen. The North American Menopause Society has noted that NSAIDs should be used at the lowest effective dose and for the shortest duration in the menopausal population. NAMS guidance is available at menopause.org.

Special Populations: When to Apply Tighter Limits

Women With Known Liver Disease

Prometrium is an oral progestogen, meaning it has substantially higher hepatic exposure than vaginal or topical progesterone preparations. Women with Child-Pugh class A or B liver disease who need endometrial protection on estrogen therapy may be better candidates for vaginal progesterone (Crinone, Endometrin), which bypasses first-pass metabolism and delivers progesterone to the uterus via a direct local effect with lower systemic and hepatic levels. In this population, limiting acetaminophen to 2,000 mg/day is consistent with AASLD guidance cited above.

Older Adults

Hepatic blood flow and CYP enzyme activity decline with age. A 70-year-old woman on continuous Prometrium 100 mg/day may clear both progesterone and acetaminophen more slowly than a 52-year-old initiating MHT. The Beers Criteria, maintained by the American Geriatrics Society, recommends acetaminophen as the preferred analgesic in older adults over NSAIDs, precisely because of NSAID-related cardiovascular and renal risks. For acetaminophen dosing in older adults, a conservative ceiling of 2,000 mg/day is supported by the AGS Beers Criteria update, accessible via NCBI.

Women With CYP2C19 Polymorphisms

CYP2C19 poor metabolizers have reduced capacity for one of the secondary progesterone clearance pathways. These individuals may show higher progesterone blood levels at standard Prometrium doses. Acetaminophen does not meaningfully interact with CYP2C19, so this polymorphism does not change acetaminophen safety in this context. However, it does mean some women may experience more pronounced Prometrium sedation and endometrial effects, and dose individualization may be appropriate.

Comparing Prometrium to Other Progestogens: Does the Interaction Risk Differ?

Not all progestogens metabolize identically. Synthetic progestins like medroxyprogesterone acetate (MPA, brand name Provera) and norethindrone are processed through different CYP pathways and have distinct interaction profiles. A comparative pharmacokinetics review in Climacteric (2018) noted that micronized progesterone produces a broader spectrum of neuroactive metabolites and relies more heavily on CYP3A4 than most synthetic progestins, which tend to favor CYP3A4 to a lesser degree for their primary metabolism.

For the specific question of acetaminophen co-administration, the interaction risk profile is similarly low across all progestogens because acetaminophen does not interfere with CYP3A4, CYP2C19, or any major progestogen clearance pathway at therapeutic doses. The hepatic metabolic load consideration applies across the class, not uniquely to micronized progesterone.

Clinical Decision Summary

For a prescriber evaluating whether to proceed with Prometrium in a patient who regularly uses acetaminophen, the decision framework is straightforward:

1. Confirm baseline LFTs are within normal limits before starting Prometrium.
2. Document total daily acetaminophen intake, including all combination products.
3. If total acetaminophen is below 3,000 mg/day and liver function is normal, no special restriction is needed for the combination.
4. If total acetaminophen exceeds 3,000 mg/day, or if the patient has liver disease or drinks alcohol regularly, reduce the acetaminophen ceiling to 2,000 mg/day and consider vaginal progesterone as an alternative to oral Prometrium.
5. Counsel the patient on hepatic warning signs and schedule LFTs annually or semi-annually if chronic acetaminophen use continues.

The STEP-1 trial architecture of weight-loss research is routinely cited as a model for rigorous dosing confirmation. No equivalent specific RCT has been conducted on the Prometrium-acetaminophen pairing, because the interaction severity does not justify that level of study. The absence of trial data here reflects the absence of significant risk, not a gap in knowledge. Current FDA label review and pharmacokinetic data provide sufficient basis for clinical guidance.

A woman on Prometrium 100 mg/day continuous who takes a maximum of 3,000 mg/day acetaminophen for well-controlled chronic pain, has normal LFTs, does not drink alcohol, and reports no hepatic symptoms requires no change to her regimen beyond routine annual monitoring.